BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
25.95
-0.69 (-2.59%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.80 - 26.82
52 week 16.26 - 28.45
Open 26.82
Vol / Avg. 14,770.00/40,916.00
Mkt cap 165.96M
P/E 38.36
Div/yield     -
EPS 0.68
Shares 6.40M
Beta 1.13
Inst. own 45%
Aug 4, 2014
Q2 2014 Biospecifics Technologies Earnings Release (Estimated) Add to calendar
Jun 24, 2014
Biospecifics Technologies Annual Stockholder Meeting
Jun 2, 2014
Biospecifics Technologies at Jefferies Global Healthcare Conference
May 19, 2014
Biospecifics Technologies at UBS Global Healthcare Conference
May 8, 2014
Q1 2014 Biospecifics Technologies Earnings Release
May 8, 2014
Q1 2014 Biospecifics Technologies Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 27.31% 36.54%
Operating margin 41.01% 54.91%
EBITD margin - 55.36%
Return on average assets 12.63% 25.39%
Return on average equity 13.20% 26.57%
Employees 5 -
CDP Score - -

Address

35 WILBUR ST
LYNBROOK, NY 11563
United States - Map
+1-516-5937000 (Phone)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for clinical indications in Dupuytren�s contracture, Peyronie�s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including lipomas and cellulite. Auxilium has an agreement with Pfizer, Inc. (Pfizer), pursuant to which Pfizer has the right to market XIAFLEX for Dupuytren�s contracture and Peyronie�s disease in 27 member countries of the European Union and 19 other European and Eurasian countries, and under the registered trademark XIAPEX (collagenase clostridium histolyticum).

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 58
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 78
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Henry Morgan Independent Director
Age: 92
Bio & Compensation  - Reuters